| 吴筱萍,张 弦,陶军秀,郑 兵,屈月清.消胀散敷脐联合腹水超滤浓缩回输治疗肝硬化顽固性腹水的疗效及对肝肾功能、电解质和生活质量的影响[J].现代生物医学进展英文版,2022,(24):4763-4767. |
| 消胀散敷脐联合腹水超滤浓缩回输治疗肝硬化顽固性腹水的疗效及对肝肾功能、电解质和生活质量的影响 |
| Effect of Xiaozhangsan Applying Umbilicus Combined with Ultrafiltration Concentration and Reinfusion of Ascites in the Treatment of Refractory Ascites Due to Liver Cirrhosis and its Effect on Liver and Kidney Function, Electrolyte and Quality of Life |
| Received:May 27, 2022 Revised:June 22, 2022 |
| DOI：10.13241/j.cnki.pmb.2022.24.032 |
| 中文关键词: 肝硬化顽固性腹水 消胀散敷脐 腹水超滤浓缩回输 疗效 肝肾功能 电解质 生活质量 |
| 英文关键词: Rrefractory ascites due to liver cirrhosis Xiaozhangsan applying umbilicus Ultrafiltration concentration and reinfusion of ascites Curative effect Liver and kidney function Electrolyte Quality of life |
| 基金项目:湖北省卫生和计划生育委员会科研项目（WJ2017M147） |
|
| Hits: 627 |
| Download times: 383 |
| 中文摘要: |
| 摘要 目的：观察消胀散敷脐联合腹水超滤浓缩回输治疗肝硬化顽固性腹水的疗效及对肝肾功能、电解质和生活质量的影响。方法：选取2017年1月-2020年12月在我院肝病科住院治疗的肝硬化顽固性腹水患者64例，根据随机数字法分为对照组（腹水超滤浓缩回输治疗，32例）和治疗组（消胀散敷脐联合腹水超滤浓缩回输治疗，32例）。观察两组治疗前和治疗4周后的疗效、腹水消退率、体质量、腹围、24 h尿量变化、肝肾功能指标、血电解质指标和生活质量测定量表简表（QOL-BREF）评分，并记录两组治疗期间不良反应（包括皮肤红疹、瘙痒等）发生情况。结果：治疗组治疗4周后的临床总有效率高于对照组（P<0.05）。治疗组治疗4周后腹水消退率显著优于对照组（P<0.05）。治疗组治疗4周后体质量、腹围小于对照组，24 h尿量多于对照组（P<0.05）。治疗组治疗4周后丙氨酸氨基转移酶（ALT）、谷草转氨酶（AST）、尿素氮（BUN）、胱抑素C(CysC)低于对照组（P<0.05）。两组治疗前、治疗4周后组间及组内对比钾（K+）、钠(Na+)、氯（Cl-）均无统计学差异（P>0.05）。治疗组治疗4周后社会关系领域、生理领域、环境领域、心理领域评分均高于对照组（P<0.05）。治疗期间两组不良反应发生率对比无统计学差异（P>0.05）。结论：消胀散敷脐联合腹水超滤浓缩回输治疗肝硬化顽固性腹水，可提高临床治疗效果，改善患者的肝肾功能和生活质量，同时对机体电解质影响不大，安全可靠。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the curative effect of Xiaozhangsan applying umbilicus combined with ultrafiltration concentration and reinfusion of ascites in the treatment of refractory ascites due to liver cirrhosis and its effect on liver and kidney function, electrolyte and quality of life. Methods: From January 2017 to December 2020, 64 patients with refractory ascites due to liver cirrhosis who were hospitalized in the Department of Hepatology of our hospital were selected, and according to the random number method, they were divided into control group (ultrafiltration concentration and reinfusion of ascites treatment, 32 cases) and treatment group (Xiaozhangsan applying umbilicus combined with ultrafiltration concentration and reinfusion of ascites treatment, 32 cases). The curative effect, ascites regression rate, body mass, abdominal circumference, 24 h urine volume change, liver and kidney function indexes, blood electrolyte indexes and quality of life questionaire abbreviated version (QOL-BREF) score of the two groups were observed before and 4 weeks after treatment, and the occurrence of adverse reactions (including skin rash, pruritus, etc.) during the treatment of the two groups were recorded. Results: The total clinical effective rate in the treatment group at 4 weeks after treatment was higher than that in the control group (P<0.05). The ascites regression rate in the treatment group at 4 weeks after treatment was significantly higher than that in the control group (P<0.05). The body weight and abdominal circumference in the treatment group at 4 weeks after treatment were lower than those in the control group, and 24 h urine volume was higher than that in the control group (P<0.05). The alanine aminotransferase (ALT), aspartate aminotransferase (AST), urea nitrogen (BUN) and cystatin C(CysC) in the treatment group at 4 weeks after treatment were lower than those in the control group (P<0.05). There were no significant differences in potassium (K+), sodium (Na+) and chlorine (Cl-) between the two groups before treatment and 4 weeks after treatment (P>0.05). The scores of social relationshipl field, physical field, environmentl field and psychologyl field in the treatment group at 4 weeks after treatment were higher than those in the control group (P<0.05). There was no statistical difference in the incidence of adverse reactions between the two groups during treatment (P>0.05). Conclusion: Xiaozhangsan applying umbilicus combined with ultrafiltration concentration and reinfusion of ascites in the treatment of refractory ascites due to liver cirrhosis can improve the clinical treatment effect, improve the liver and kidney function and quality of life of patients, and have little impact on the body electrolyte, which is safe and reliable. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
